Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
2004 1
2005 1
2006 2
2007 1
2008 1
2009 1
2011 1
2012 2
2013 1
2014 2
2015 1
2016 1
2017 6
2018 4
2019 4
2020 3
2021 4
2022 7
2023 5
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Results by year

Filters applied: . Clear all
Page 1
Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions.
Zhou C, Tang KJ, Cho BC, Liu B, Paz-Ares L, Cheng S, Kitazono S, Thiagarajan M, Goldman JW, Sabari JK, Sanborn RE, Mansfield AS, Hung JY, Boyer M, Popat S, Mourão Dias J, Felip E, Majem M, Gumus M, Kim SW, Ono A, Xie J, Bhattacharya A, Agrawal T, Shreeve SM, Knoblauch RE, Park K, Girard N; PAPILLON Investigators. Zhou C, et al. N Engl J Med. 2023 Nov 30;389(22):2039-2051. doi: 10.1056/NEJMoa2306441. Epub 2023 Oct 21. N Engl J Med. 2023. PMID: 37870976 Clinical Trial.
Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer.
Provencio M, Nadal E, González-Larriba JL, Martínez-Martí A, Bernabé R, Bosch-Barrera J, Casal-Rubio J, Calvo V, Insa A, Ponce S, Reguart N, de Castro J, Mosquera J, Cobo M, Aguilar A, López Vivanco G, Camps C, López-Castro R, Morán T, Barneto I, Rodríguez-Abreu D, Serna-Blasco R, Benítez R, Aguado de la Rosa C, Palmero R, Hernando-Trancho F, Martín-López J, Cruz-Bermúdez A, Massuti B, Romero A. Provencio M, et al. Among authors: aguilar a. N Engl J Med. 2023 Aug 10;389(6):504-513. doi: 10.1056/NEJMoa2215530. Epub 2023 Jun 28. N Engl J Med. 2023. PMID: 37379158 Clinical Trial.
Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.
Drilon A, Camidge DR, Lin JJ, Kim SW, Solomon BJ, Dziadziuszko R, Besse B, Goto K, de Langen AJ, Wolf J, Lee KH, Popat S, Springfeld C, Nagasaka M, Felip E, Yang N, Velcheti V, Lu S, Kao S, Dooms C, Krebs MG, Yao W, Beg MS, Hu X, Moro-Sibilot D, Cheema P, Stopatschinskaja S, Mehta M, Trone D, Graber A, Sims G, Yuan Y, Cho BC; TRIDENT-1 Investigators. Drilon A, et al. N Engl J Med. 2024 Jan 11;390(2):118-131. doi: 10.1056/NEJMoa2302299. N Engl J Med. 2024. PMID: 38197815 Clinical Trial.
KRAS inhibitors, approved.
Rosell R, Aguilar A, Pedraz C, Chaib I. Rosell R, et al. Among authors: aguilar a. Nat Cancer. 2021 Dec;2(12):1254-1256. doi: 10.1038/s43018-021-00289-3. Nat Cancer. 2021. PMID: 35121930 No abstract available.
The role of biomarkers in stage III non-small cell lung cancer.
Rosell R, González-Cao M, Ito M, Santarpia M, Aguilar A, Codony-Servat J. Rosell R, et al. Among authors: aguilar a. Expert Rev Respir Med. 2023 Jan-Jun;17(6):469-480. doi: 10.1080/17476348.2023.2223985. Epub 2023 Jun 15. Expert Rev Respir Med. 2023. PMID: 37317885 Review.
Author Correction: KRAS inhibitors, approved.
Rosell R, Aguilar A, Pedraz C, Chaib I. Rosell R, et al. Among authors: aguilar a. Nat Cancer. 2022 Apr;3(4):518. doi: 10.1038/s43018-022-00372-3. Nat Cancer. 2022. PMID: 35379985 No abstract available.
Tumor mutational burden as predictive factor of response to immunotherapy.
Gonzalez-Cao M, Viteri S, Karachaliou N, Aguilar A, García-Mosquera JJ, Rosell R. Gonzalez-Cao M, et al. Among authors: aguilar a. Transl Lung Cancer Res. 2018 Dec;7(Suppl 4):S358-S361. doi: 10.21037/tlcr.2018.10.03. Transl Lung Cancer Res. 2018. PMID: 30705855 Free PMC article. No abstract available.
Targeted therapies for KRAS-mutant non-small cell lung cancer: from preclinical studies to clinical development-a narrative review.
Santarpia M, Ciappina G, Spagnolo CC, Squeri A, Passalacqua MI, Aguilar A, Gonzalez-Cao M, Giovannetti E, Silvestris N, Rosell R. Santarpia M, et al. Among authors: aguilar a. Transl Lung Cancer Res. 2023 Feb 28;12(2):346-368. doi: 10.21037/tlcr-22-639. Epub 2023 Feb 20. Transl Lung Cancer Res. 2023. PMID: 36895930 Free PMC article. Review.
Non-Small-Cell Lung Cancer Signaling Pathways, Metabolism, and PD-1/PD-L1 Antibodies.
Santarpia M, Aguilar A, Chaib I, Cardona AF, Fancelli S, Laguia F, Bracht JWP, Cao P, Molina-Vila MA, Karachaliou N, Rosell R. Santarpia M, et al. Among authors: aguilar a. Cancers (Basel). 2020 Jun 5;12(6):1475. doi: 10.3390/cancers12061475. Cancers (Basel). 2020. PMID: 32516941 Free PMC article. Review.
49 results